Inclusion Criteria:  Signed informed consent obtained prior to conducting any study-specific screening procedures. Willing and able to understand the nature of this study and to comply with both the study as well as follow-up procedures for the duration of the study. Age ≥ 18 years old with newly-diagnosed Acute Myeloid Leukemia (AML) ECOG performance status must be ≤ 2 Peripheral white blood cell (WBC) count < 30,000/µL. For those patients with a WBC count above this threshold who are requiring cytoreduction, hydroxyurea is permitted during screening and through Cycle 1, Day 7 in order to reduce WBC count to < 30,000/µL.  Adequate organ function as evidenced by the following laboratory findings:  Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or < 3 x ULN for patients with Gilbert's Syndrome Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN Creatinine clearance > 60 mL/min Ability to take oral medication and a willingness to adhere to the beta blocker and lisinopril regimen QT interval corrects to < 480ms on one electrocardiogram (ECG) at screening Echocardiogram demonstrating an ejection fraction ≥ 50% prior to the initiation of induction chemotherapy  Exclusion Criteria:  Ongoing use of any beta blocker, ACEi, or angiotensin II receptor agonist (ARB) at the time of pre-enrollment screening. Uncontrolled, intercurrent illnesses including but not limited to symptomatic unstable angina pectoris, cardiac arrhythmias not well controlled with medications, myocardial infarction in the 6 months preceding registration or psychiatric illness/social situations that would limit compliance with study requirements as determined by the study personnel, all at the discretion of the treating oncologist. Patient receiving concurrent investigational agents, or those who have received an investigational agent within one week of registration. Females who are pregnant or lactating. For females of reproductive potential: a negative pregnancy test is traditionally required prior to initiation of induction chemotherapy, due to the risk of teratogenicity to the fetus, and patients are advised to either abstain from sexual activity or use reliable contraception while undergoing treatment. All patients will additionally be counseled on the teratogenic effects of ACE inhibitors, in addition to their induction chemotherapy, and counseled to adhere to the recommendations outlined above. History of other malignancies in the 12 months preceding registration with the exception of in-situ cancers, non-muscle invasive bladder cancer, prostate cancer basal or squamous cell skin cancers. Life-threatening illnesses other than AML, uncontrolled medical conditions or organ system dysfunction that, in the investigator's opinion, could compromise the patient's safety or study outcomes. Radiographic evidence of extramedullary disease Acute Promyelocytic Leukemia (APL) or AML with active central nervous system (CNS) involvement. Active, untreated and/or severe infections as determined by the treating oncologist. Active and uncontrolled HIV infection, defined as infection possessing a PCR-detectable viral load Active infection with the Hepatitis B Virus, defined as having a positive Hepatitis B surface antigen or PCR-detectable viral load Active infection with the Hepatitis C Virus, defined as having a PCR-detectable viral load. History of hematopoietic stem cell transplant (HSCT) with active graft vs host disease, immunosuppression other than low-dose prednisone (≤ 5mg) or calcineurin inhibitors within the four weeks preceding registration Moderate or severe mitral or aortic valve disease, as determined by echocardiography Congestive heart failure as clinically diagnosed by treating oncologist at the time of presentation for induction chemotherapy, or documented diagnosed by a previous physician. History of (repaired or unrepaired) congenital heart disease Significant liver disease, including cirrhosis or history of transplant or hepatorenal syndrome) Bradycardia (defined as baseline resting heart rate ≤ 60 beats per minute) or third degree atrioventricular heart block at presentation for induction chemotherapy. Baseline resting systolic blood pressure < 95mmHg at presentation for induction chemotherapy. Documented allergy to beta blockers or ACE inhibitors.